A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome?
- 29 June 2002
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 359 (9325) , 2215-2216
- https://doi.org/10.1016/s0140-6736(02)09315-7
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Angptl3 regulates lipid metabolism in miceNature Genetics, 2002
- New drug targets for type 2 diabetes and the metabolic syndromeNature, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Insulin resistance and cardiovascular diseaseJournal of Clinical Investigation, 2000
- Identification of a Mammalian Angiopoietin-Related Protein Expressed Specifically in LiverGenomics, 1999
- Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1 H NMR spectroscopy studyDiabetologia, 1999
- Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical ImplicationsDiabetes, 1995
- Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implicationsDiabetes, 1995
- What if Minkowski Had Been Ageusic? An Alternative Angle on DiabetesScience, 1992